Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19368
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDang, Christa-
dc.contributor.authorHarrington, Karra D-
dc.contributor.authorLim, Yen Ying-
dc.contributor.authorAmes, David-
dc.contributor.authorHassenstab, Jason-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorYassi, Nawaf-
dc.contributor.authorHickey, Martha-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorRobertson, Joanne-
dc.contributor.authorSohrabi, Hamid R-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorWeinborn, Michael-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorMaruff, Paul-
dc.date2018-08-22-
dc.date.accessioned2018-09-17T01:47:02Z-
dc.date.available2018-09-17T01:47:02Z-
dc.date.issued2018-
dc.identifier.citationJournal of Alzheimer's disease : JAD 2018; 65(4): 1313-1325-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19368-
dc.description.abstractPreclinical Alzheimer's disease (AD) is defined by cerebral amyloid-β positivity (Aβ+) in cognitively normal (CN) older adults. To estimate the risk of progression to the symptomatic stages of AD due to PET Aβ+ and the extent that progression was influenced by other demographic, genetic, and clinical characteristics in a large prospective study. Fine-Gray subdistribution modeling was used to examine the risk of progression from CN to MCI/dementia due to Aβ+, APOEɛ4 carriage, and their interaction in the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging CN cohort (n = 599) over 8 years. 17.7% Aβ+ and 8.1% Aβ-progressed over 8 years (OR: 2.43). Risk of progression for Aβ+ was 65-104% greater than Aβ-. Aβ+ APOEɛ4 carriers were at 348% greater risk than all other participants. Significant risk factors of progression in Aβ+ were age (HR: 1.05), PET SUVR (HR: 2.49) and APOE ɛ4 carriage (HR: 2.63); only age was a significant risk factor in Aβ-(HR: 1.09). Aβ-progressors were not near the threshold for Aβ+. These relationships were not moderated by hypertension, diabetes, obesity, or stroke/TIA. Aβ+ is an important prognostic marker for progression from CN to MCI/dementia in older adults and APOEɛ4 carriage provides further predictive value in the presence of Aβ+. These data suggest that Aβ-associated clinical progression is consistent with clinical-pathological models of AD, whereas progression in the absence of elevated Aβ deposition may be the result of neuropathological processes other than AD that accumulate with age.-
dc.language.isoeng-
dc.subjectAPOEɛ4-
dc.subjectAlzheimer’s disease-
dc.subjectbiomarkers-
dc.subjectdementia-
dc.subjectmild cognitive impairment-
dc.titleRelationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of Alzheimer's disease : JAD-
dc.identifier.affiliationCogState Ltd., Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationCooperative Research Centre for Mental Health, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Psychiatry, Academic Unit for Psychiatry of Old Age, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationCharles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USAen
dc.identifier.affiliationDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USAen
dc.identifier.affiliationDepartment of Psychological and Brain Sciences, Washington University, St. Louis, MO, USAen
dc.identifier.affiliationCollaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australiaen
dc.identifier.affiliationSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia, Australiaen
dc.identifier.affiliationDepartment of Medicine and Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australiaen
dc.identifier.affiliationAustralian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australiaen
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences, University of WA, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationCSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, QLD, Australiaen
dc.identifier.affiliationSchool of Psychological Science, University of Western Australia, Crawley, WA, Australiaen
dc.identifier.doi10.3233/JAD-180507-
dc.identifier.orcid0000-0003-3910-2453-
dc.identifier.pubmedid30149452-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.